InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.54
(
-0.19%
)
Bitcoin
65,162.41
(
0.30%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: micanwait post# 12852

Monday, 09/26/2011 9:34:40 AM

Monday, September 26, 2011 9:34:40 AM

Post# of 80490

If approved as a front line therapy, what would be the size of the market?



The front line market potential is >$2 billion and growing. The problem is ponatinib would be facing competition against second generation agents like Tasigna and Sprycel, and against Gleevec which would be available as a generic by the time Ariad completes a head-to-head phase III trial.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up